Advancements in In Vivo CAR-T Therapies

This chapter focuses on the innovative strides in in vivo CAR-T cell therapies, detailing recent clinical trials for programs targeting CD19 and CD22. It emphasizes the role of data from non-human primates in demonstrating therapeutic efficacy and contrasts their approach with competitors while underscoring the importance of data integrity in the manufacturing process. Discussions also explore the future potential of these therapies, including redosing options and creating accessible treatments for patients with hematologic malignancies.